Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,264.00
Bid: 12,280.00
Ask: 12,282.00
Change: 146.00 (1.20%)
Spread: 2.00 (0.016%)
Open: 12,244.00
High: 12,384.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-European stocks flat despite rise in cyclicals

Tue, 12th Jan 2021 10:06

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)

* Cyclical stocks lead gains again

* London's FTSE hit by stronger pound

* Maersk gains after Berenberg upgrade
(Updates to market close)

By Sruthi Shankar

Jan 12 (Reuters) - European stocks closed flat on Tuesday,
with economically sensitive sectors including banks, automakers
and oil supporting markets across the continent.

The regional STOXX 600 index closed up 0.05% after
a mixed session, while Germany's DAX rose 0.1%,
France's CAC inched 0.2% lower and Britain's FTSE 100
fell 0.7%.

Investors are awaiting the start of the U.S. earnings season
this week as well as clarity on fiscal spending plans under
incoming U.S. President Joe Biden, who takes office on Jan. 20.

In Europe, automakers jumped 1.7% to lead gains
after Renault, BMW and VW
reported 2020 sales.

Their U.S. carmaking rivals also got a boost after General
Motors announced its entry into the growing electric
delivery vehicle business.

Other cyclicals such as banks, travel and leisure
and oil and gas extended last week's rally on
hopes that a larger U.S. stimulus under the incoming Biden
administration will spur faster economic recovery.

Oil majors BP and Royal Dutch Shell gained
close to 2% as crude prices hit an 11-month high on tighter
supply and expectations for a drop in U.S. inventories.

Still, losses in defensive sectors such as healthcare,
utilities and consumer staples checked gains in most markets.

"Investors are still wondering where the next big catalyst
for further upside will come from, and are painfully aware that
the COVID-19 crisis remains untamed despite the introduction of
vaccination programmes," Chris Beauchamp, chief market analyst
at IG wrote in a client note.

Britain's exporter-heavy FTSE 100 underperformed
other European markets, hit by a stronger pound and a surge in
new COVID-19 cases.

Companies listed on Europe's STOXX 600 are expected to
report a 26.3% drop in fourth-quarter earnings, data from
Refinitiv I/B/E/S shows, as restrictions to control soaring
coronavirus cases slowed an economic recovery.

That comes ahead of a clear improvement predicted for the
first two quarters of 2021, when earnings are set to rise 40.4%
and 75.1% respectively.

Maersk rose 3.4% after brokerage Berenberg
upgraded the Danish shipping company's shares to "buy", saying
earnings momentum driven by freight prices could see it run
higher.

Swiss online pharmacy chain Zur Rose hit a record
high, surging almost 15% to the top of STOXX 600, after BofA
Global Research started coverage with "buy" rating.
(Reporting by Amal S and Sruthi Shankar in Bengaluru; Editing
by Subhranshu Sahu, Arun Koyyur and Alexander Smith)

More News
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.